Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after switching than patients with continuous (n = 260) or terminated treatment (n = 41). Study Limitations: The reason for intermittent treatment was not recorded. The intermittently treated patients may be a heterogeneous group and a limitation is that it cannot be determined whether less than continuous use was offered to handle negative aspects. Conclusion: Patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients.

Keywords:
Biologic agents, Intermittent treatment, Continuous treatment, Psoriasis, Register
1.
Lomholt G: Prevalence of skin diseases in a population; a census study from the Faroe Islands. Dan Med Bull 1964;11:1-7.
2.
Läkemedelsverket [Medical Products Agency]: [Pharmaceutical treatment in psoriasis - new recommendation.] Information from MPA 2011;4:22 (in Swedish).
3.
Schmitt-Egenolf M: Psoriasis therapy in real life: the need for registries. Dermatology 2006;213:327-330.
4.
Schmitt-Egenolf M: PsoReg - the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology 2007;214:112-117.
5.
Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M: Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology 2012;225:326-332.
6.
Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB: Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol 2013;31(4 suppl 78):S63-S70.
7.
FASS, Pharmaceutical Specialties in Sweden. www.fass.se (accessed June 18, 2014).
8.
Fredriksson T, Pettersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-244.
9.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
10.
EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
11.
Dolan P: Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
12.
Novartis: Novartis Cosentyx™ receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients. http://hugin.info/134323/R/1873177/659629.pdf (accessed December 19, 2014).
13.
European Medicines Agency: European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144941.pdf (accessed December 19, 2014).
14.
Persson E, Waernbaum I: Estimating a marginal causal odds ratio in a case-control design: analyzing the effect of low birth weight on the risk of type 1 diabetes mellitus. Stat Med 2013;32:2500-2512.
15.
Rubin DB: Estimating causal effects of treatments in randomized and non-randomized studies. J Educ Psychol 1974;66:688-701.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.